Monogram Technologies Inc. (NASDAQ: MGRM) shares are experiencing a substantial rally on the U.S. stock charts today, rising 73.40% to reach $5.71 at the time of last check. The dramatic surge in MGRM stock follows the announcement of a definitive merger agreement with Zimmer Biomet, under which Zimmer will acquire all outstanding shares of Monogram for an upfront cash payment of $4.04 per share. This values the company’s equity at approximately $177 million and its enterprise value at roughly $168 million.
Additional Value via Contingent Rights
A non-tradeable contingent value right (CVR) will be awarded to Monogram common shareholders in addition to the original cash payment. Holders of this CVR are eligible to earn an extra $12.37 in cash per share, subject to the fulfillment of certain revenue, regulatory, and product development milestones through 2030. The transaction has received unanimous approval from both MGRM’s and Zimmer Biomet’s boards of directors.
Revolutionizing Surgical Robotics
Monogram’s cutting-edge CT-based, semi-autonomous robotic system for total knee arthroplasty (TKA), which integrates artificial intelligence for navigation, received FDA 510(k) clearance in March 2025. It is slated for commercialization using Zimmer Biomet implants by early 2027. MGRM is also developing a fully autonomous robotic solution with the potential to significantly enhance safety, precision, and clinical outcomes across a broader range of surgical procedures.
Strategic Integration and Future Prospects
Following the completion of the transaction, Zimmer Biomet aims to become the first company in orthopedics to provide a fully autonomous surgical robot. Monogram’s proprietary robotic technology will augment Zimmer Biomet’s ROSA Robotics platform and strengthen its already diverse and surgeon-focused suite of technologies.
With Zimmer Biomet’s global reach and infrastructure, MGRM’s innovations are expected to scale rapidly. The acquisition will be financed through Zimmer Biomet’s cash reserves and available debt facilities, with no expected disruption to its capital allocation strategy. The deal is pending regulatory and shareholder approvals, with the closing anticipated later in 2025.
